Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-α activator, prevents pancreatic degeneration in obese and diabetic rats

Pancreas

Volumn 26, Issue 3, 2003, Pages 286-291

  Jia, Dongmei ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Bezafibrate; Inflammation; Otsuka Long Evans Tokushima Fatty (OLETF) rat; Pancreatic degeneration; PPAR hyperlipidemia

Indexed keywords

BEZAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEGENERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM CELL; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPID DIET; LIPID METABOLISM; NONHUMAN; OBESITY; PANCREAS DISEASE; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

ACTINS; ANIMALS; ANTILIPEMIC AGENTS; BEZAFIBRATE; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, TYPE 2; INSULIN; LIPIDS; OBESITY; ORGAN SIZE; PANCREAS; RATS; RATS, INBRED OLETF; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0037380305     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200304000-00013     Document Type: Article

References (49)

1. Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complication: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-8.
2. Funakoshi A, Miyasaka K, Jimi A, et al. Little or no expression of the cholecystokinin-A receptor gene in the pancreas of diabetes rats (Otsuka Long-Evans Tokushima Fatty = OLETF rats). Biochem Biophys Res Commun 1994;199: 482-8.
3. Nakamura H, Kihara Y, Tashiro M, et al. Expression and the CCK-A receptor-mediated biological functions in Otsuka Long-Evans Tokushima fatty (OLETF) rats. J Gastroenterol 1998;33:702-9.
4. Povoski SP, Zhou W, Longnecker DS, et al. Stimulation of in vivo pancreatic growth in the rat is mediated specifically by way of cholecystokinin-A receptors. Gastroenterology 1994;107:1135-46.
5. Otsuki M, Williams JA. Amylase secretion by isolated pancreatic acini after chronic cholecystokinin treatment in vivo. Am J Physiol Gastrointest Liver Physiol 1983;244:G683-88.
6. Yamamoto M, Jia DM, Fukumitsu KI, et al. Metabolic abnormalities in the genetically obesc and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by α-glucosidase inhibitor. Metabolism 1999;48:347-54.
7. Jia, DM, Tabaru A, Nakamura H, et al. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. Metabolism 2000;49:1167-75.
8. Akiyama T, Tachibana I, Shirohara H, et al. High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat. Diabetes Res Clin Pract 1996;31:27-35.
9. Uchida T, Tsuchiya R, Harada N, et al. Ischemic changes in the pancreas of Watanabe heritable hyper-lipidemic (WHHL) rabbits. Int J Pancreatol 1988;3: 261-7.
10. Saharia P, Margolis S, Zuidema GD, et al. Acute pancreatitis with hyperlipidemia studies with an isolated pcrfused canine pancreas. Surgery 1977;82:60-7.
11. Aoyama T, Peters JM, Iritani N, et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor a (PPAR α). J Biol Chem 1998;273:5678-84.
12. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor α in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999;10:151-9.
13. Stewart MW, Dyer RG, Alberti KG, et al. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabet Med 1995;12:250-7.
14. Goa KL, Barradell LB, Plosker GL. Bezafibrate: an update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52:725-53.
15. Pill J, Wolff S, Stegmeier K, et al. Effect of bezafibrate on serum lipids in normo- and spontaneously hyperlipidemic rats. Methods Find Exp Clin Pharmacol 1988; 10:487-92.
16. Bondar RJL, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chim Acta 1974;20:586-90.
17. Morgan CR, Lazarow AL. Immnnoassay of insulin: two antibody system. Diabetes 1963;12:115-26.
18. Lowry OH, Rosenrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
19. Labarca C, Paigen K. A simple, rapid and sensitive DNA assay procedure. Anal Biochem 1980;102:344-52.
20. Ceska M, Birath K, Brown B. A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Clin Chim Acta 1958; 26:437-44.
21. Erlanger BE, Kokowasky N, Cohen W. The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 1961;95:271-8.
22. Whitaker JP. A rapid and specific method for the determination of pancreatic lipase in serum and urine. Clin Chim Acta 1973;44:133-8.
23. Miyasaka K, Masuda M, Ohta M, et al. Role of cholecystokinin (CCK): a receptor in pancreatic growth in rats during suckling period: a study in naturally occurring CCK-A receptor gene "knockout" rat. Pancreas 1997;14:103-5.
24. Miyasaka K, Ohta M, Kanai S, et al. Role of cholecystokinin (CCK) A receptor for pancreatic growth after weaning: a study in a new model without gene expression of CCK A receptor. Pancreas 1996;12:351-6.
25. Green GM, Levan VH, Liddle RA. Plasma cholecystokinin and pancreatic growth during adaptation to dietary protein. Am J Physiol Gastrointest Liver Physiol 1986;251:G70-4.
26. Gokc B, Printz H, Koop I, et al. Endogenous CCK release and pancreatic growth in rats after feeding a protcase inhibitor (camostat). Pancreas 1986;1:509-15.
27. Folsch UR, Winckler K, Wormsley KG. Influence of repeated administration of cholecystokinin and secretin on the pancreas of the rat. Scand J Gastroenterol 1978;13:663-71.
28. Okauchi N, Mizuno A, Yoshimoto S, et al. Is caloric restriction effective in preventing diabetes mellitus in the Otsuka Long Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus? Diabetes Res Clin Pract 1995;27:97-106.
29. Shima K, Shi K, Mizuno A, et al. Exercise training has a long-lasting effect on prevention of non-insulin-dependent diabetes mellitus on Otsuka-Long-Evans-Tokushima Fatty rats. Metabolism 1996;45:475-80.
30. Kopin AS, Mathes WF, McBride EW, et al. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J Clin Invest 1999;103:383-91.
31. Lacourse KA, Swanbcrg LJ, Gillespie PJ, et al. Pancreatic function in CCK-deficient mice: adaptation to dietary protein dose not require CCK. Am J Physiol Gastrointest Liver Physiol 1999;276:G1302-9.
32. Williams JA, Goldfine ID. The insulin-pancreatic acinar axis. Diabetes 1985;34: 980-6.
33. Kato M, Ohkuma S, Kataoka K, et al. Mechanisms for pancreatic hypertrophy induced by Iong-term administration of bethanechol. Eur J Pharmacol 1994;129: 47-55.
34. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33.
35. Jia DM, Fukumitsu KI, Tabaru A, et al. Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. Am J Physiol Regulatory Integrative Comp Physiol 2001;280:R1332-40.
36. Saurcr L, Reber P, Schaffner T, et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterology 2000;118:356-67.
37. Lupi R, Dotta F, Marselli L, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002;51:1437-42.
38. Zhou YT, Grayburn P, Shimabukuro M, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000;97:1784-9.
39. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
40. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR-α but not by PPAR-γ activators. Nature 1998;395: 790-3.
41. Cninetti G, Groglio S, Antonucci M, et al. Activation of proliferator-activated receptors-α and -β induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-80.
42. DiMagno EP, Layer P, Clain JE. Chronic pancreatitis. In: Go VLW, Di Magno EP, Gardner JD, et al., eds. The pancreas: biology pathobiology and disease, 2nd ed. New York: Raven, 1993;665-706.
43. Sarles H, Bernard JP, Gullo L. Pathogenesis of chronic pancreatitis. Gut 1990; 31:629-32.
44. Sarles H, Bernard JP, Johnson C. Pathogenesis and epidemiology of chronic pancreatitis. Ann Rev Med 1989;40:453-68.
45. Kennedy RH, Bockmann DE, Uscanga L, et al. Pancreatic extracellular matrix alterations in chronic pancreatitis. Pancreas 1987;2:61-72.
46. Casini A, Galli A, Pignalosa P, et al. Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. J Pathol 2000;192:81-9.
47. Luttenberger T, Schmid-Kotsas A, Menke A, et al. Platelet-derived growth factors stimulate proliferation and extracellular matrix synthesis of pancreatic stellate cells: implications in pathogenesis of pancreas fibrosis. Lab Invest 2000;80: 47-55.
48. Schneider E, Schmid-Kotsas A, Zhao J, et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am J Physiol Cell Physiol 2001;281:C532-43.
49. Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats, and humans. Gastroenterology 1998; 115:421-32.